Overview

Electroencephalography (EEG) Biomarkers of Response in Depression

Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
There are two specific aims of this project: 1. To identify physiologic indicators of venlafaxine treatment response using quantitative EEG (QEEG) cordance, and to determine if cordance changes are specifically associated with response to venlafaxine 2. To identify predictors of placebo response in major depression using QEEG cordance/bispectral index (BIS) and neuropsychological testing
Phase:
Phase 4
Details
Lead Sponsor:
University of California, Los Angeles
Collaborators:
Medtronic - MITG
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Venlafaxine Hydrochloride